Financials · VNRX

VolitionRX Limited (VNRX) financials

For the twelve months ended Sep 30, 2026, VolitionRX Limited reported $3.44M of revenue and -$24.09M of net income.

Revenue, TTM
$3.44M
Revenue growth, YoY
+134.0%
Net income, TTM
-$24.09M
Net margin
-699.3%
Free cash flow, TTM
-$20.59M
Cash
$2.40M
Total debt
$6.71M
P/S
1.95
Market cap
$6.7M
Annual revenue$1.73M
FY2019FY2025
Annual net income-$23.36M
FY2016FY2025
Annual free cash flow-$19.77M
FY2016FY2025

VNRX revenue and earnings growth

VNRX revenueQ3 2026$1.61M

Quarter YoY
+157.3%
QoQ
+304.8%
FY YoY
+40.0%
5Y CAGR
+164.1%

VNRX revenue was $1.61M in fiscal Q3 2026 (ended Sep 30, 2026), up 157.3% from a year earlier and up 304.8% from the prior quarter. For the full fiscal 2025 it was $1.73M, up 40.0% from fiscal 2024. Compound annual growth was +164.1% over 5 years. It rose in 5 of the last 6 fiscal years. Fiscal 2025 is the highest of the 10 fiscal years on file.

VNRX net incomeQ3 2026-$3.80M

VNRX net income was -$3.80M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$5.38M a year earlier. For the full fiscal 2025 it was -$23.36M, compared with -$26.97M in fiscal 2024.

VNRX EPSQ3 2026-$0.21

VNRX diluted EPS was -$0.21 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2024 it was -$6.20, compared with -$10.00 in fiscal 2023.

VNRX free cash flowQ3 2026-$4.63M

VNRX free cash flow was -$4.63M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$3.63M a year earlier. For the full fiscal 2025 it was -$19.77M, compared with -$26.17M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue$1.73M$1.23M$775.3K$306.4K$90.0K$13.4K$17.1K---
Research and development$10.08M$14.41M$19.55M$15.33M$13.02M$14.53M$10.36M$10.91M$8.03M$7.90M
Selling, general and admin$9.46M$8.49M$10.37M$10.18M$11.68M$5.65M$4.73M$5.82M$5.83M$4.18M
Operating income-$21.74M-$27.02M-$35.99M-$31.78M-$28.33M-$21.25M-$16.04M-$17.90M-$14.70M-$12.43M
Interest expense----$155.8K$129.8K$126.6K-$110.9K$73.1K$20.4K
Net income-$23.36M-$26.97M-$35.68M-$30.60M-$26.99M-$20.40M-$16.10M-$18.01M-$14.77M-$11.91M
EPS, basic-----$10.20-$9.00-$8.20-$11.40-$11.20-$10.40
EPS, diluted--$6.20-$10.00--$10.20-$9.00-$8.20-$11.40-$11.20-$10.40
Diluted shares5.3M4.3M3.6M-2.6M2.3M2.0M1.6M1.3M1.2M

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$1.12M$3.26M$20.73M$10.87M$20.58M$19.44M$16.97M$13.43M$10.12M$21.68M
Receivables$317.8K$110.6K$242.6K$72.6K$12.5K$7.1K$0---
Current assets$2.06M$4.06M$21.85M$12.17M$21.98M$20.33M$17.56M$13.90M$10.57M$22.01M
Total assets$6.90M$9.40M$27.95M$18.30M$27.49M$26.15M$21.29M$17.49M$14.62M$24.73M
Current liabilities$12.23M$7.79M$8.94M$17.39M$6.52M$6.24M$3.86M$2.33M$2.29M$2.03M
Short-term debt$890.6K$860.2K$1.21M$1.07M$797.9K$841.3K$647.6K$416.6K$443.9K$30.7K
Long-term debt$5.82M$3.95M$3.62M$2.78M$2.27M$2.61M$2.20M$1.98M$1.31M$432.0K
Total debt$6.71M$4.81M$4.83M$3.85M$3.07M$3.45M$2.84M$2.40M$1.76M$462.7K
Total liabilities$42.49M$35.51M$36.66M$21.42M$9.77M$9.86M$7.09M$5.35M$4.67M$3.56M
Shareholders' equity-$34.25M-$26.11M-$8.71M-$3.13M$17.72M$16.29M$14.20M$12.14M$9.96M$21.18M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow-$19.68M-$25.89M-$18.06M-$15.28M-$20.85M-$16.46M-$12.74M-$14.73M-$12.19M-$8.86M
Capital expenditures$89.6K$277.5K$1.08M$1.57M$973.6K$1.94M$511.3K-$301.8K$1.43M$415.1K
Free cash flow-$19.77M-$26.17M-$19.15M-$16.85M-$21.83M-$18.41M-$13.25M-$15.03M-$13.62M-$9.28M
Investing cash flow-$89.6K-$573.9K-$1.08M-$1.57M-$973.6K-$1.65M-$511.3K-$301.8K-$1.43M-$415.1K
Financing cash flow$17.09M$8.66M$28.98M$6.94M$22.86M$20.62M$16.93M$17.97M$1.97M$25.19M
Share repurchases-$0$31.8K$0------
Stock-based compensation$1.74M$1.27M$2.29M$3.11M$2.45M-$1.46M$2.57M$2.44M$1.68M
Depreciation and amortization$983.7K$1.11M$1.15M$936.1K$945.4K$716.2K$676.8K$636.4K$528.2K$309.4K

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue growth, YoY40.0%59.1%153.0%240.3%570.3%-21.4%----
Operating margin-1258.5%-2190.9%-4641.8%-10372.4%-31469.0%-158176.2%-93840.2%---
Net margin-1352.2%-2186.3%-4601.7%-9986.7%-29977.0%-151859.6%-94168.5%---
Free cash flow margin-1144.7%-2121.7%-2469.6%-5498.8%-24243.3%-137015.6%-77507.7%---
Return on equity-----152.3%-125.2%-113.4%-148.3%-148.3%-56.2%
Return on assets-338.4%-286.9%-127.6%-167.2%-98.2%-78.0%-75.6%-103.0%-101.0%-48.1%
Current ratio0.170.522.440.703.373.264.555.964.6110.82
Debt to equity----0.170.210.200.200.180.02

Source: XBRL data VolitionRX Limited files with the SEC, latest filing dated Nov 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported May 14, 2026.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

VNRX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
VNRX$3.44M+134.0%-$24.09M-699.3%$6.7M
GH$1.28B+41.7%-$485.07M-37.9%$20.52B
GRAL$166.60M+17.5%-$406.18M-243.8%$5.21B
NTRA$2.91B+37.4%-$164.71M-5.7%$46.27B
MYGN$803.60M-2.6%-$129.10M-16.1%$542.9M

VNRX FAQ

7 questions
  • What is VNRX revenue?
    VolitionRX Limited (VNRX) reported $3.44M of revenue for the twelve months ended Sep 30, 2026. That is up 134.0% from the year before. Revenue for fiscal 2025 was $1.73M.
  • Is VNRX profitable?
    No. VolitionRX Limited reported a net loss of $24.09M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does VNRX have?
    VolitionRX Limited reported $2.40M in cash and cash equivalents and $6.71M of debt on its most recent balance sheet in SEC filings.
  • How fast is VNRX revenue growing?
    VolitionRX Limited's revenue changed +40.0% in fiscal 2025, to $1.73M. Its compound annual growth rate was +164.1% over 5 years.
  • What is VNRX free cash flow?
    VolitionRX Limited generated -$20.59M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$20.52M less capital expenditures.
  • When did VNRX last report financial results?
    The latest statements here come from VolitionRX Limited's 10-Q filed on Nov 12, 2026, covering the period ended Sep 30, 2026.
  • Where does this VNRX financial data come from?
    Quantisnow builds these statements from the structured XBRL data VolitionRX Limited files with the SEC. It is provided for information only and is not investment advice.